Novo Nordisk is working on long-acting GLP-1 agents
Novo Nordisk is developing a new obesity candidate that may only need to be taken once a year, according to Danish newspaper Berlingske.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.